 Boca Raton, FL., July 14, 2021 GLOBE NEWSWIRE -- INmune Bio, Inc. NASDAQ: INMB the Company or INmune Bio, a clinical-stage immunology company focused on developing treatments that harness a patients innate immune system to fight disease, today announced that it has entered into a definitive agreement with one healthcare focused institutional investor and one family office for the purchase and sale of 1,818,182 shares of its common stock at a price of 22.00 per share for gross proceeds of approximately 40 million in a registered direct offering. The closing of the offering is expected to occur on or about July 16, 2021, subject to the satisfaction of customary closing conditions. 